Libtayo Approved as First Adjuvant Immunotherapy for CSCC
FDA has approved Regeneron’s PD-1 inhibitor Libtayo (cemiplimab-rwlc) as adjuvant therapy for adults with cutaneous squamous cell carcinoma (CSCC)...
InterCure Reports Surging Revenue, Positive Cash Flow in H1
InterCure reported first-half 2025 revenue of NIS 130 million, its eleventh straight period of positive adjusted EBITDA at 10%...
VIVUS Announces Qsymia Price Reduction at Costco Pharmacies
VIVUS has cut the retail cash price of Qsymia, its phentermine/topiramate extended‑release capsule for chronic weight management, to under...
Journey Medical Confirms October 2025 Investor Conferences
Journey Medical will meet investors at two New York conferences in October: the 4th Annual ROTH Healthcare Opportunities Conference...
Nurexone’s Promising Results for Glaucoma Vision Recovery
Nurexone Biologic reported new preclinical data for ExoPTEN, an exosome-delivered siRNA therapy targeting PTEN, showing a reproducible, dose-dependent restoration...
Nasus Pharma Expands NS002 Epinephrine Development Agreement
Nasus Pharma has signed comprehensive agreements with Aptar to support clinical development and planned commercialization of NS002, an intranasal...
Catalyst Pharmaceuticals Announces New Scientific Presentations
Catalyst Pharmaceuticals will present a cluster of real-world evidence analyses across the October congresses, spanning the Child Neurology Society,...
Pharma Co. Unveils ‘B-FREE’ Chronic Babesiosis Trial Name
60 Degrees Pharmaceuticals is launching B-FREE, a Phase 2 open-label trial evaluating the ARAKODA (tafenoquine) regimen as a potential...
Novo Nordisk to Acquire Akero Therapeutics for $5.2 Billion
Novo Nordisk has agreed to acquire Akero Therapeutics for up to $5.2 billion in cash, adding the FGF21 analogue...
Revolutionary Acquisition: Digital Utilities Ventures Rebrands
Digital Utilities Ventures, operating as Easy Environmental Solutions, has completed FINRA’s corporate action process, finalizing its acquisition of Lifestyle...